Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Claritin-D 24-hour swallowing difficulty addressed anew in July 23 "Dear Doctor" letter.

Executive Summary

SCHERING CLARITIN-D 12-HOUR MAY BE USED IN PATIENTS WITH SWALLOWING DIFFICULTY who should not receive the 24-hour version of the loratadine/pseudoephedrine product, the company says in a July 23 "Dear Doctor" letter to prescribers. "For these patients, you may want to consider prescribing Claritin-D 12-hour (5 mg loratadine/120 mg pseudoephedrine sulfate, USP) extended-release tablets instead of Claritin-D 24-hour," the letter states.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel